HGHector Galindo

Hector Galindo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hector Galindo has a total of 432 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ameloblastoma con mutación BRAF p.V600E: estado actual de las terapias dirigidas

    by Manuel Felipe Concha Vera, Juan Pablo Vargas Buratovic, José Miguel López Valladares, Francisco Javier Rojas Cuéllar, Héctor Gonzalo Galindo Aranibar, Camila Foncea Riquelme de la Barrera

    El ameloblastoma corresponde a una neoplasia odontogénica benigna, caracterizada por un comportamiento clínico localmente agresivo y una alta tasa de recurrencia. La identificación de la mutación BRAF p.V600E en estos tumores ha permitido el desarrollo de terapias dirigidas con inhibidores de BRAF y MEK, las cuales se han posicionado como una alternativa menos invasiva y con menor morbilidad en casos localmente avanzados. Actualmente, el uso de estas terapias ha sido documentado a través de reportes de caso y series clínicas, evidenciando una reducción del volumen tumoral permitiendo realizar procedimientos quirúrgicos más conservadores. En este contexto, la presente revisión de la literatura tiene como objetivo describir la vía MAPK, analizar su relevancia en la patogénesis del ameloblastoma e integrar la evidencia existente sobre el uso de inhibidores de BRAF en su tratamiento. Para ello, se realizó una búsqueda en las bases de datos PubMed y Embase, incluyendo artículos en inglés que abordaran mecanismos moleculares, implicancia clínica de la mutación y resultados terapéuticos con inhibidores de la vía MAPK. Asimismo, se discuten los desafíos en relación con la estandarización del tratamiento, la evaluación de la respuesta a largo plazo y la necesidad de estudios clínicos.

  • Open Access

    Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series

    by Patricio Salas, Maria Eliana Solovera, Felipe Bannura, Matias Muñoz-Medel, Miguel Cordova-Delgado, Cesar Sánchez, Carolina Ibáñez, Marcelo Garrido, Érica Koch, Francisco Acevedo, et al.

    Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series Patricio Salas1, Maria Eliana S

  • Open Access

    A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability

    by Mauricio P. Pinto, Miguel Córdova-Delgado, Ignacio N. Retamal, Matías Muñoz-Medel, M. Loreto Bravo, Doris Durán, Francisco Villanueva, César Sanchez, Francisco Acevedo, Sebastián Mondaca, et al.

    Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost and complex techniques and consequently their impact in the clinic has remained limited. Additionally, most of these studies are based on European, Asian, or North American GC cohorts. Herein, we report a molecular classification of Chilean GC patients into five subtypes, based on immunohistochemical (IHC) and in situ hybridization (ISH) methods. These were Epstein–Barr virus positive (EBV+), mismatch repair-deficient (MMR-D), epithelial to mesenchymal transition (EMT)-like, and accumulated (p53+) or undetected p53 (p53−). Given its lower costs this system has the potential for clinical applicability. Our results confirm relevant molecular alterations previously reported by TCGA and ACRG. We confirm EBV+ and MMR-D patients had the best prognosis and could be candidates for immunotherapy. Conversely, EMT-like displayed the poorest prognosis; our data suggest FGFR2 or KRAS could serve as potential actionable targets for these patients. Finally, we propose a low-cost step-by-step stratification system for GC patients. To the best of our knowledge, this is the first Latin American report on a molecular classification for GC. Pending further validation, this stratification system could be implemented into the routine clinic


  • Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non–Small-Cell Lung Cancer

    by Gonzalo Pizarro, Mauricio P. Pinto, Matías Muñoz-Medel, Miguel Cordova-Delgado, M. Loreto Bravo, Bruno Nervi, César Sánchez, Carolina Ibañez, José Peña, Benjamín Walbaum, et al.


  • First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution

    by Benjamin Walbaum, Francisco Acevedo, Lidia Medina, M. Loreto Bravo, Tomas Merino, Mauricio Camus, Francisco Dominguez, Sebastian Mondaca, Hector Galindo, Bruno Nervi, et al.

    Objective: Clinical guidelines recommend the use of endocrine therapy (ET) in advanced hormone receptor positive (HR+) human epidermal growth factor receptor type 2 negative (HER2-) breast cancer (BC) patients in the absence of visceral disease or ET resistance. Furthermore, studies indicate similar response and survival rates using ET or cytotoxic chemotherapy (CT). Methods: Herein, we assessed clinical characteristics, type of systemic therapy and survival rates of advanced HR + HER2- BC patients in our database. Results: A total of 172 advanced HR + HER2-BC patients were treated at our institution between 1997 and 2019. Sixty percent received first-line ET (4% received combined ET). Median age of this subset was 55 years (range: 30-86). Similarly, the median age of patients that received CT was 54 years (range: 21-83). Over time, 30% of patients received ET in the 2000-2005 period; this increased to 70% in the 2016-2019 period (p = 0.045). Overall survival (OS) was 97 months and 51 months for patients treated with ET or CT, respectively (p = 0.002). Conclusions: To the best of our knowledge this is the first study assessing the use of ET in Chilean advanced HR + HER2- BC patients. Several patients in our institution receive CT without indication. The increase in ET usage over time can be attributed to better and faster immunohistochemical detection methods for Estrogen Receptor (ER), changes in educational and government policies, and a wider variety of ET options. Finally, clinical trials have failed to demonstrate a substantial benefit of CT over ET in this setting.


  • Open Access

    Retrospective Analysis of Chilean and Mexican GI Stromal Tumor Registries: A Tale of Two Latin American Realities

    by Germán Calderillo, Matías Muñoz-Medel, Edelmira Carbajal, Miguel Córdova-Delgado, Doris Durán, Ignacio N. Retamal, Piga Fernández, Absalón Espinoza, Rodrigo Salas, María de la Paz Mastretta, et al.

    PURPOSE Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America. PATIENTS AND METHODS Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients' clinical characteristics, including survival rates, through retrospective analysis. RESULTS Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries. CONCLUSION To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias. (c) 2020 by American Society of Clinical Oncology


  • Open Access

    Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution

    by Cristóbal Maiz, Fernando Silva, Francisco Domínguez, Héctor Galindo, Mauricio Camus, Augusto León, David Oddó, Alejandra Villarroel, Dravna Razmilic, María Elena Navarro, et al.

    Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution Cristóbal Maiz1,


  • Open Access

    High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study

    by Miguel Cordova-Delgado, Mauricio P. Pinto, Ignacio N. Retamal, Matías Muñoz-Medel, María Loreto Bravo, María F. Fernández, Betzabé Cisternas, Sebastián Mondaca, César Sanchez, Hector Galindo, et al.

    Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients.


  • Top Cited Papers

    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    by Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko, et al.


  • Open Access

    Prevalence of EGFR Mutations and Clinico-Pathological Characteristics of Chilean Lung Cancer Patients

    by Roger Gejman, Sergio Gonzalez, Matias Munoz Medel, Bruno Nervi, Cesar Sanchez, Carolina Ibáñez, Jose Peña, Jorge Madrid, Juan Briones, Patricia Perez, et al.

    Background: Lung cancer (LC) is the second leading cause of cancer death in Chile, causing >3,000 deaths everyyear. Epidemiological LC data in Chile is scarce and scattered. Here, we aimed to quantify the prevalence of EpidermalGrowth Factor Receptor (EGFR) gene mutations in a Chilean cancer center. These data may identify individuals thatcould benefit from targeted therapies such as Tyrosine Kinase Inhibitors (TKIs). Methods: A total of 1,405 Biopsiesfrom 1,381 LC patients were retrospectively analyzed retrieving clinical data from EGFR mutants including age,gender, histological type, smoking habits and type of EGFR mutation. We also analyzed overall survival (OS) rates.Results: From all patients 21.7% had clinically relevant EGFR mutations, and a median age at diagnosis of 65 years.Most were female (64%), classified as adenocarcinomas (94.5%), and non-smokers/light smokers (93.1%). The mostprevalent mutation was exon-19 deletions (50.6%) followed by Leucine-to Arginine 858; OS was 15 months. Clinicalfollow-up information was available for 83 patients. The use of TKIs in these patients significantly improved OS.Conclusion: The prevalence of EGFR mutations in the studied population was 21.7%, comparable to other countriesin Latin America. The most frequent EGFR mutation was exon-19 deletion, OS in this group was 15 months, and TKIssignificantly improved OS.